• The IPI is an active player of the Swiss Health Foreign Policy (SHFP), which was approved by the Federal Council in 2019.
  • The trilateral study conducted by the WHO, WIPO and the WTO "promoting access to medical technologies and innovation" addresses the questions and challenges in the intersections between public health, innovation and intellectual property.
  • In May 2011 a working group of the Swiss government (co-led by the IPI) published an overview on the implementation and contribution of Swiss actors (PDF) to the WHO's Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property.

A number of organisations and initiatives which carry out important work to promote innovation and access to medicines and are already in contact with the IPI:

  • The Access to Medicines Foundation publishes an index every two years which ranks the efforts made by the 20 largest research-based pharmaceutical companies to make their relevant medicines accessible to poor populations and how successful they are at doing so.
  • The Medicines Patent Pool (MPP) is a foundation under Swiss law. It is fully financed by UNITAID. The foundation negotiates licence agreements with patent holders, primarily for HIV treatments. Since the end of 2015 the foundation has also been involved in the negotiation of licences for drugs to treat co-infection diseases such as tuberculosis and hepatitis C.
  • WIPO's Re:SEARCH platform is a consortium designed to encourage research and development of new drugs, vaccines and diagnostics for neglected diseases such as malaria and tuberculosis. It provides access to the intellectual property of certain medicines and to data as well as to relevant contacts for research activities.
EN: War diese Seite hilfreich?

Was this page helpful?*